Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today is providing a number of strategic updates, including its recently executed option agreement with Incyte ...

Early data from the ADAPT JR trial suggest efgartigimod may benefit adolescents with generalized myasthenia gravis, a rare ...

Biogen beat Wall Street estimates for third-quarter profit, helped by better-than-expected sales of some of its multiple ...

Biogen cut its annual profit forecast on Thursday, as it expects to take a hit of $1.25 per share from R&D related charges ...

Detailed price information for Royalty Pharma Plc Cl A (RPRX-Q) from The Globe and Mail including charting and trades.

Following a lengthy R&D process, two new molecules from Biogen could add much-needed treatments for a disease that’s been difficult to pin down.

Oral presentation to share first-of-its-kind longitudinal gene expression data in IgA nephropathy, unveiling novel insights ...

Ironically enough, his initial downfall had nothing to do with Daraprim. Soon after he became infamous, federal prosecutors ...

With $185 million in series A funding and an army of experienced leaders in its ranks, Braveheart Bio is setting off to joust ...

"Spinogenix’s ALS hopeful to advance to registrational trial" was originally created and published by Clinical Trials Arena, ...

Fintel reports that on November 3, 2025, Bernstein maintained coverage of Biogen (NasdaqGS:BIIB) with a Market Perform ...

As momentum for Biogen’s newer drugs for neurological disorders builds at a slow and steady pace, it appears that the company ...